6.96
-0.16 (-2.25%)
| Penutupan Terdahulu | 7.12 |
| Buka | 7.10 |
| Jumlah Dagangan | 173,053 |
| Purata Dagangan (3B) | 281,453 |
| Modal Pasaran | 182,422,352 |
| Harga / Jualan (P/S) | 3.59 |
| Harga / Buku (P/B) | 3.55 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Feb 2026 |
| Margin Keuntungan | -97.49% |
| Margin Operasi (TTM) | -108.82% |
| EPS Cair (TTM) | -2.14 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 72.70% |
| Nisbah Semasa (MRQ) | 14.82 |
| Aliran Tunai Operasi (OCF TTM) | -41.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.25 M |
| Pulangan Atas Aset (ROA TTM) | -26.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -76.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | CVRx, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | 2.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.70 |
|
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.26% |
| % Dimiliki oleh Institusi | 73.63% |
| Julat 52 Minggu | ||
| Median | 10.00 (43.68%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 13 Feb 2026 | 10.00 (43.68%) | Beli | 4.95 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JAIN MUDIT K. | 5.48 | - | 47,400 | 288,858 |
| Jumlah Keseluruhan Kuantiti Bersih | 47,400 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 288,858 | |||
| Purata Pembelian Keseluruhan ($) | 5.48 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| JAIN MUDIT K. | Pengarah | 20 Feb 2026 | Beli (+) | 46,800 | 6.11 | 285,948 |
| JAIN MUDIT K. | Pengarah | 18 Feb 2026 | Beli (+) | 600 | 4.85 | 2,910 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 |
| 22 Jan 2026 | Pengumuman | CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population |
| 12 Jan 2026 | Pengumuman | CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance |
| 06 Jan 2026 | Pengumuman | CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy |
| 22 Dec 2025 | Pengumuman | CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |